Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence

The MIRACLE study (NCT07596615), led by the Mario Negri Institute for Pharmacological Research and set to begin recruiting in 2026, investigates a newly recognized pathway by which aging cells become chronically inflamed: the leakage of mitochondrial RNA (mtRNA) out of mitochondria and into the cell's cytoplasm, where it can trigger immune alarm signals. As mitochondria age and deteriorate, their membranes become leaky, releasing RNA molecules that the immune system misreads as a sign of viral infection, switching on type I interferon responses and accelerating cellular senescence — the state in which cells stop dividing but remain metabolically active and release inflammatory signals. The trial will recruit adult volunteers across three distinct age groups, allowing researchers to map how these molecular events change across the human lifespan. Skin biopsies will provide fibroblasts and blood draws will yield immune cells (PBMCs), both studied in the lab to characterize the biology and test therapeutic strategies first identified in animal or cell models. Blood-based measurements of inflammatory proteins and whole-blood gene expression will capture systemic effects beyond the cells themselves. The study represents one of the first human trials designed to directly test whether mtRNA release is a tractable target for slowing inflammaging — the chronic low-grade inflammation that underlies most age-related disease. If the experimental interventions reduce mtRNA-driven inflammation in human cells, it could open a new class of anti-aging strategies distinct from existing senolytics or NAD+ boosters.

• This is a not-yet-recruiting trial (planned start May 2026); no outcome data are available. All findings listed here are study objectives, not results.
• Primary objective: characterize the relationship between donor age and the degree of mtRNA release, type I interferon pathway activation, and cellular senescence markers in skin fibroblasts and PBMCs across three adult age groups.
• Secondary objective: test preclinically identified therapeutic strategies for their ability to reduce mtRNA-driven inflammation and senescence in the isolated human cells, with systemic inflammatory and transcriptomic signatures serving as additional endpoints.

MIRACLE is a prospective, cross-sectional mechanistic trial enrolling adult participants stratified into three age groups (specific age brackets not yet disclosed in the registry). Each participant undergoes a skin punch biopsy (to generate primary fibroblast cultures) and a blood draw (to isolate PBMCs, serum, plasma, and whole-blood RNA). Isolated cells will be characterized for mtRNA release, mitochondrial stress markers, senescence-associated secretory phenotype (SASP) components, and type I interferon signatures, and will then be used in ex-vivo intervention experiments. Circulating inflammatory mediators and systemic transcriptional profiles will also be assessed from the blood fractions. Sample size and specific intervention agents are not yet disclosed in the trial registry.

Because the trial has not yet begun recruiting, no efficacy, safety, or mechanistic data exist; all framework statements carry low confidence and are based solely on the registered protocol. The cross-sectional design can establish age-associated correlations between mtRNA release and inflammation but cannot prove causality or determine whether reducing mtRNA release in humans translates to clinical benefit over time. Ex-vivo intervention experiments on isolated fibroblasts and PBMCs may not fully recapitulate the complex tissue microenvironment or systemic intercellular communication present in vivo. A natural follow-on experiment would be a longitudinal interventional trial administering the most promising agent identified here to older adults, with functional aging outcomes (physical performance, immune rejuvenation, biomarker trajectories) as endpoints.

The MIRACLE study sits at the intersection of two converging lines of inquiry well represented in this corpus. It directly extends [§71], which identifies mitochondrial dysfunction and mtRNA-related innate immune signaling as pathological drivers in polycystic kidney disease, by asking whether the same mtRNA-release mechanism is a generalizable feature of human aging across tissues. The study parallels [§116], which uses mouse models to map tissue-specific mitochondrial metabolic deficits during aging, but MIRACLE advances the translational frontier by moving into primary human cells and testing intervention strategies rather than characterization alone. The focus on type I interferon activation downstream of mtRNA also contextually parallels [§136], where mitophagy suppression of the NLRP3 inflammasome in peripheral nerve repair demonstrates that controlling mitochondrial distress signals is therapeutically actionable — MIRACLE asks an analogous question in the aging context. Finally, the use of PBMCs and serum transcriptomics to capture systemic immune-aging signatures resonates with [§28], which shows that extracellular vesicle and mitochondrial transfer signals reshape T-helper cell function in human disease, underscoring that mitochondrial stress is communicated systemically and not confined to the cell of origin.

• The Role of Mitochondria in Polycystic Kidney Disease
  Directly investigates mtRNA release and mitochondrial innate immune signaling as a disease driver, providing the closest mechanistic parallel and making it the essential companion read for understanding the MIRACLE study's biological rationale.
• Impact of aldehyde dehydrogenase 2 deficiency on tissue-specific mitochondrial metabolism in aging mice
  Characterizes tissue-specific mitochondrial metabolic decline across aging in mice, offering a complementary preclinical framework against which MIRACLE's human cross-sectional findings can eventually be benchmarked.
• Hirudin Promotes Peripheral Nerve Repair by Enhancing Mitophagy to Suppress NLRP3 Inflammasome Activation
  Demonstrates that enhancing mitophagy to suppress mitochondrial danger signaling (NLRP3 inflammasome) is therapeutically effective in a repair context, raising the question of whether analogous mitophagy-boosting or mtRNA-blocking strategies could work in MIRACLE's aging model.
• Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma
  Shows that mitochondrial stress signals are communicated between immune cells via extracellular vesicles in human disease, directly relevant to MIRACLE's plan to measure systemic transcriptional and inflammatory signatures in blood alongside cell-intrinsic changes.
• Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
  A placebo-controlled human trial of urolithin A — a mitophagy activator — provides a rare example of an interventional study targeting mitochondrial quality control in humans, serving as a methodological and translational reference point for what MIRACLE's ex-vivo intervention findings might eventually lead to clinically.